Oramed (OTCBB: ORMP) is developing an orally ingestible soft gel insulin capsule for the treatment of diabetes and it has successfully completed its exploratory Phase 1A clinical trial... click here for the Oramed's press release.
Blog Archive
-
▼
2007
(88)
-
▼
August
(15)
- Needle-Free Drug Delivery Technology for Diabetes ...
- BodyTel Scientific to Exhibit the GlucoTel System ...
- Pfizer and Bristol-Myers Squibb Worldwide Collabor...
- Teijin and Chugai, agreement to co-develop Ipsen's...
- Cannasat Therapeutics, Commence Phase 1 Study of C...
- AtheroGenics , Phase III clinical trial of AGI-106...
- Blood Glucose Meter, Medtronic and LifeScan Annou...
- Sirtris Pharmaceuticals, SRT501 product candidate ...
- Blood Glucose Meter, Medtronic and Bayer Diabetes ...
- Novo Nordisk, Liraglutide improves glucose control
- Diabetic Neuropathic Pain, UCB's subsidiary SCHWAR...
- Oramed oral insulin gel capsule
- CombinatoRx CRx-401 for Type 2 Diabetes
- Avigen, Neuropathic Pain : Clinical Development fo...
- a news diabetes blog
-
▼
August
(15)
Wednesday, August 15, 2007
Oramed oral insulin gel capsule
Oramed (OTCBB: ORMP) is developing an orally ingestible soft gel insulin capsule for the treatment of diabetes and it has successfully completed its exploratory Phase 1A clinical trial... click here for the Oramed's press release.
